The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19

Authors:

Katunina E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4): 101‑106

DOI: 10.17116/jnevro2021121041101

Read: 18203 times

Contact the author
Table of contents

AMANTADINE IN THE TREATMENT OF PARKINSON’S DISEASE. NEW OPPORTUNITIES IN THE CONTEXT OF COVID-19
AMANTADINE IN THE TREATMENT OF PARKINSON’S DISEASE. NEW OPPORTUNITIES IN THE CONTEXT OF COVID-19

To cite this article:

Katunina EA. Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):101‑106. (In Russ.)
https://doi.org/10.17116/jnevro2021121041101

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Change of speech diso­rders during bila­teral deep stimulation of the subthalamic nucleus of the brain in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):59-65
Sleep diso­rders after COVID-19 in patients with primary headaches. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):127-132
Effe­ctiveness and tole­rability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):90-98
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Atte­ndance of oral surgeons per one inha­bitant per year in the subjects of the Russian Fede­ration in 2017—2023. Stomatology. 2025;(3):53-56
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Atte­ndance of dental surgeons for diseases in the Russian Fede­ration in 2017—2023. Stomatology. 2025;(4):62-65
Sarcoid reaction with focal inte­rstitial fibrosis in a COVID-19 patient with persistence of Sars-Cov-2 virus nucleocapsid and adhe­sion proteins in sarcoid granulomas and lung tissue. Russian Journal of Archive of Pathology. 2025;(4):54-57
Abstract:

The article presents data from recent studies on the mechanisms of action and clinical efficacy of amantadines, and also describes a possible protective effect against COVID-19.

Keywords:

Parkinson’s disease
amantadines
dyskinesias

Authors:

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Received:

09.11.2020

Accepted:

02.12.2020

Close metadata

References:

  1. Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:7:1168-1170.
  2. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096-1099. https://doi.org/10.1212/WNL.0b013e31824e8f0d
  3. Metman LV, Del Dotto P, van Den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50(5):1323-1326. https://doi.org/10.1212/WNL.50.5.1323
  4. Luginger E, Wenning GK, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2000;15(5):873-878. https://doi.org/10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I "> " target="_blank">https://doi.org/10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I
  5. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82-85. 
  6. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrin GI, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5-15.  https://doi.org/10.1111/j.1468-1331.2012.03866.x
  7. Thomas A, Iacono D, Luciano AL, Armellino K., Iorio A Di., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141-143. PMID: 14707325. PMCID: PMC1757492.
  8. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25(10):1357-1363. https://doi.org/10.1002/mds.23034
  9. Kong M, Ba M, Ren C, Yu L, Dong S, Yu G, Liang H. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson’s disease. Journal Oncotarget. 2017;8(34):57316-57326. https://doi.org/10.18632/oncotarget.17622
  10. Fox SH, Katzenschlager R, Lim SY, Barton B, Rob M A de Bie, Seppi K, Coelho M, Sampaio C. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33:1248-1266. https://doi.org/10.1002/mds.27372
  11. Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S, COPARK Study Group. Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study Drugs Aging. 2020; 37(3):215-223.  https://doi.org/10.1007/s40266-019-00740-2
  12. Kestenbaum M, Snineh MA, Nussbaum T, Gadoth A, Rosenberg A, Hindi A, Zitser J, Thaler A, Giladi N, Gurevich T. Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center. Isr Med Assoc. 2019;12(21):812-816.  https://doi.org/10.3233/JPD-202078
  13. Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 1997;3:211-214.  https://doi.org/10.1016/S1353-8020(97)00022-9
  14. Youn J, Shin H, Kim JS, Cho JW. Preliminary study of intravenous amantadine treatment for ataxia management in patients with probable multiple system atrophywith predominant cerebellar ataxia. J Mov Disord. 2012;5:1-4.  https://doi.org/10.14802/jmd.12001
  15. Wenning GK. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol. 2005;28:225-227.  https://doi.org/10.1097/01.wnf.0000183240.47960.f0
  16. Kim A, Kim YE, Yun JY, Kim HJ, Yang HJ, Lee WW, Shin CW, Park H, Jung YJ, Kim A, Kim Y, Jang M, Jeon B. Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial J Mov Disord. 2018;11(2):65-71.  https://doi.org/10.14802/jmd.18005
  17. Bandini F, Pierantozzi M, Bodis-Wollner I. The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson’s disease. A clinical and electrophysiological study. J Neural Transm (Vienna). 2002;109:41-51.  https://doi.org/10.1007/s702-002-8235-5
  18. Inzelberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, Logi Ch, Rossi C, Klein C, Rabey JM. Association between Amantadine and the onset of dementia in Parkinson’s disease. Mov Disord. 2006;21:1375-1379. https://doi.org/10.1002/mds.20968
  19. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ. Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Brain. 2011;134:979-986.  https://doi.org/10.1093/brain/awr028
  20. Nikolaus S, Wittsack HJ, Beu M, Antke C, Hautzel H, Wickrath F, Müller-Lutz A, De Souza Silva MA, Huston JP, Antoch G, Müller HW. Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity. Pharmacology Biochemistry and Behavior. 2019;179:156-170.  https://doi.org/10.1016/j.pbb.2018.12.010
  21. Shtok VN, Fedorova NV. Bolezn’ Parkinsona. In: Shtok VN, Ivanova-Smolenskaya IA, Levin OS. Ekstrapiramidnye rasstroystva: rukovodstvo po lecheniyu. M.: MEDpress-inform; 2002. (In Russ.).
  22. Turski L, Bressler K, Rettig KJ, Loschmann P-A, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 1991;349:414-418.  https://doi.org/10.1038/349414a0
  23. Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, Mannisto PT, Hong JS. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia? Neuropharmacology. 2012;62:2:1162. https://doi.org/10.1016/j.neuropharm.2011.04.030
  24. Kim C, Lee SJ. Controlling the mass action of alpha-synuclein in Parkinson’s disease. J Neurochem. 2008;107:2:303-316.  https://doi.org/10.1111/j.1471-4159.2008.05612.x
  25. Melki R. Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J Parkinsons Dis. 2015;5:2:217-227.  https://doi.org/10.3233/JPD-150543
  26. Roman A, Rogoz Z, Kubera M, Nawrat D, Nalepa I. Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacol Rep. 2009;61:1069-1077. https://doi.org/10.1016/S1734-1140(09)70167-7
  27. Caumont AS, Octave JN, Hermans E. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci Lett. 2006;394:3:196-201.  https://doi.org/10.1016/j.neulet.2005.10.027
  28. Rogoz Z, Skuza G, Legutko B. Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol. 2008;60:6:817-826. PMID: 19211973.
  29. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment is an independent predictor of improved survival in parkinson’s disease. Neurology. 1996;46:6:1551-1556. https://doi.org/10.1212/WNL.46.6.1551
  30. Shealy CN, Weeth JB, Mercier D. Livedo reticularis in patients with parkinsonism receiving amantadine. JAMA. 1970;212:1522-1523. https://doi.org/10.1001/jama.1970.03170220076019
  31. Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol. 2005;252:1155-1166. https://doi.org/10.1007/s00415-005-0967-9
  32. Shulman LM, Minagar A, Sharma K, Weiner WJ. Amantadine induced peripheral neuropathy. Neurology. 1999;53:1862-1865. https://doi.org/10.1212/WNL.53.8.1862
  33. Chang KC, Jeong JH, Kim MK, Wee WR, Lee JH, Seok Jeon B. The effect of amantadine on corneal endothelium in subjects with Parkinson’s disease. Ophthalmology. 2010;117:1214-1219. https://doi.org/10.1016/j.ophtha.2009.10.039
  34. Daggumilli S, Vanathi M, Ganger A, Goyal V, Tandon R. Corneal evaluation in patients with parkinsonism on long-term amantadine therapy. Cornea. 2019;38(9):1131-1136. https://doi.org/10.1097/ICO.0000000000001951
  35. Demirci S, Gunes A, Koyuncuoglu HR, Tok L, Tok O. Evaluation of corneal parameters in patients with Parkinson’s disease. Neurol Sci. 2016;37:1247-1252. https://doi.org/10.1007/s10072-016-2574-1
  36. Aksoy D, Ortak H, Kurt S, Cevik E, Cevik B. Central corneal thickness and its relationship to Parkinson’s disease severity. Can J Ophthalmol. 2014;49:152-156.  https://doi.org/10.1016/j.jcjo.2013.12.010
  37. McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016;129:21-38.  https://doi.org/10.1016/j.antiviral.2016.01.012
  38. Abreu G, Aguilar M, Covarrubias DH. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020;140:109755. https://doi.org/10.1016/j.mehy.2020.109755
  39. Smieszek SP, Prychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression; potential therapy for COVID19 [published online ahead of print April 05, 2020]. bioRxiv. 2020. https://doi.org/10.1101/2020.04.05.026187
  40. Honegger UE, Quack G, Wiesmann UN. Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta -adrenergic transmission. Pharmacol Toxicol. 1993;20273(4)-208.  https://doi.org/10.1111/j.1600-0773.1993.tb01564.x
  41. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163. https://doi.org/10.1016/j.msard.2020.102163
  42. Borra AC. Does amantadine have a protective effect against COVID-19? Polish J Neurol & Neurosurg. 2020;54:3:284-285, indexed in PubMed: 32495926. https://doi.org/10.5603/PJNNS.a2020.0041
  43. Araujo R, Aranda-Martinez JD, Aranda-Abreu GE. Amantadine Treatment for People with COVID-19. Arch Med Res. 2020. https://doi.org/10.1016/j.arcmed.2020.06.009
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.